The efficacy of taking traditional Chinese medicine orally in renal interstitial fibrosis

Abstract

Background: By now, the incidence of chronic kidney disease (CKD) is increasing. The development of various CKD is attributed to the continuous aggravation of renal interstitial fibrosis (RIF) in the process of end-stage renal disease (ESRD). Oral treatment of traditional Chinese medicine (TCM) is one of the therapies for RIF. Randomized controlled trials (RCTs) of TCM treatment RIF have been reported, but its effectiveness and safety have yet been systematically investigated. Therefore, through the systematic analysis and meta-analysis, our study will summarize the effectiveness and safety of oral treatment RIF of TCM, in order to provides scientific reference for clinical practice. Methods: This protocol follows Preferred Reporting Items for Systematic Evaluation and Meta-Analysis. RCTs will be only selected. Such databases as the PubMed, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Excerpt Medical Database (Embase), WanFan Data, Chinese Biomedical Literature Database (CBM), WHO International Clinical Trials Registry Platform will be searched from the inception to June, 2020 to collect the RCTs about taking TCM orally in treating RIF. The literature according to the inclusion and exclusion criteria, data-extracted and the methodological quality evaluated will be performed independently by 2 reviewers. The clinical outcomes including renal function indices (Scr, BUN, 24-hour urinary protein quantity) and Indicators of RIF (TGF-β1, Notch1, Jagged-1). The risk of bias included in the RCTs will be evaluated by the bias risk assessment tool provided in the Cochrane System Evaluation Manual 5.1.0. Review Manager 5.3 provided by the Cochrane collaboration network will be used to process the data. Results and conclusion: Some more targeted and practical results about the efficacy of taking TCM orally in RIF have been provided by our study. The available evidence suggests that the therapeutic effects of combining TCM with Western medicine therapies is much better for RIF than Western medicine therapies only.

Network pharmacology and bioinformatics study on the treatment of renal fibrosis with persicae semen-carthami flos drug pair

“…Traditional Chinese medicine has the advantages of small toxic side effects and multi-target and multi-pathway. It has been clinically proven that traditional Chinese medicine has good efficacy in improving RF and delaying slow renal failure, [7] so the development of new traditional Chinese medicine preparations is extremely valuable.…”

Network Pharmacology Analysis and Machine-Learning Models Confirmed the Ability of YiShen HuoXue Decoction to Alleviate Renal Fibrosis by Inhibiting Pyroptosis

“… 15 A meta-analysis suggested that the combination of TCM and Western medicine was much more effective in treating RF than Western medicine alone. 16 YiShen HuoXue decoction (YSHXD) is composed of Rhei Radix et Rhizoma (Da Huang, DH), Angelica sinensis Radix (Dang Gui, DG), Achyranthes bidentata Radix (Niu Xi, NX), Salviae Miltiorrhizae Radix et Rhizoma (Dan Shen, DS), Notoginseng Radix et Rhizoma (San Qi, SQ), Carthami Flos (Hong Hua, HH) and Astragali Radix (Huang Qi, HQ). Modern pharmacological studies have confirmed that DH, DS, HQ, DG, SQ, NX, HH and their components can inhibit RF and inflammatory responses and promote kidney repair.…”

Exploring the mechanism of Shendi Bushen capsule in anti-renal fibrosis using metabolomics theory and network analysis

“…After years of research, the advantages of TCM in improving RF and delaying chronic renal failure (CRF) have been gradually proved. 5 Shendi Bushen capsule (SDBS) is a Chinese patent medicine derived from the classic prescription of traditional Chinese medicine. It is suitable for the decompensation period and renal failure period of CRF in the middle and late stages of RF.…”